GenSight Biologics (Euronext: SIGHT), a company specializing in gene therapies for retinal and central nervous system diseases, has announced a successful capital increase totaling over €9.2 million. The offering included the issuance of new shares with warrants attached through reserved and private placements, predominantly subscribed by US investors. The price per attached share warrant bundle was set at €0.395. This financial influx is expected to bolster GenSight’s strategic goals, including the resumption of early access programs in France for LHON patients in Q3 2024, according to CEO Laurence Rodriguez, affirmed the confidence of the investment community in GenSight’s vision and trajectory. This development coincides with the resumption of trading of the company’s shares on the Euronext exchange.

Biotechnology, Private Equity,France, United States